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Although CEBPA mutations are among the most common genetic abnormalities in acute myeloid leukemia
(AML), the transformation mechanism remains largely obscure. In this issue of Cancer Cell, Zhang and
colleagues report that SOX4 is a direct target and crucial mediator of C/EBPa mutants in AML, revealing a
potential therapeutic avenue.Mutations in CEBPA, which encodes the
protein CCAAT/enhancer binding protein
alpha (C/EBPa) and is critical for granulo-
cytic differentiation, are frequently found
in acute myeloid leukemia (AML) and
account for up to 20% of normal karyo-
type-AML (Zeisig et al., 2012). Two-thirds
of CEBPA mutations are bi-allelic, in
which N-terminal frame-shift mutations
in one allele lead to increased expression
of the 30 kDa isoform, whereas C-terminal
in-frame mutations in the other allele
result in C/EBPa mutants with compro-
mised DNA binding/homodimerization
properties. The pathological functions of
bi-allelic CEBPA mutations in AML have
been clearly demonstrated using knock-
in mouse models (Bereshchenko et al.,
2009). C-terminal mutations enhance the
proliferation of long-term hematopoietic
stem cells (LT-HSCs), whereas N-terminal
mutations allowmyeloid progenitor devel-
opment for leukemic transformation.
Consistently, mice carrying bi-allelic mu-
tations develop myeloid leukemia with a
significantly shorter latency than those
with single mutations. The role of CEBPA
mutations has also been demonstrated in
human systems. Human hematopoietic
progenitors overexpressing either single
or both C/EBPa mutants mimic certain
features of CEBPA-mutated AML cells
but fail to initiate leukemia, suggesting
that additional events are required for full
blown leukemia (Quintana-Bustamante
et al., 2012). In spite of its clear causative
role, the transformation mechanisms and
critical downstream targets of CEBPA
mutations are still largely unknown.
In this issue of Cancer Cell, Zhang et al.
(2013) have identified SOX4 as a critical
mediator of C/EBPa functions in normal
and malignant hematopoiesis. In a sys-tematic shRNA screen of the top 30 upre-
gulated genes in mouse hematopoietic
stem progenitor cell (HSPC)-enriched
LinSca-1+c-Kit+ (LSK) population car-
rying Cebpa knockout (KO) alleles, spe-
cific knock-down of SOX4 resulted in
the strongest suppression of serial replat-
ing capacity of Cebpa KO LSK cells.
Conversely, overexpression of SOX4 in
normal LSK and myeloid progenitors
conferred enhanced serial replating abil-
ity, indicating a critical function of SOX4
in promoting self-renewal and blocking
myelo-differentiation in normal and
Cebpa KO HSPCs. Further, direct tran-
scription and functional links between
C/EBPa and SOX4 came from transcrip-
tional and biochemical studies. Expres-
sion of Cebpa increased as cells matured
from LT-HSCs to differentiated myeloid
progenitors, whereas the expression of
Sox4, which is suppressed by C/EBPa,
declined during hematopoietic differen-
tiation (Figure 1A). In contrast to the
previously described indirect repressive
mechanism via E2F family members,
ChIP-seq analysis together with lucif-
erase reporter and EMSA assays con-
sistently revealed direct and specific
C/EBPa-binding in the Sox4 locus that
was required for C/EBPa-mediated
repression of Sox4 expression. To investi-
gate the in vivo functional interaction
between Cebpa and Sox4, the authors
compared the hematopoietic activities of
single and compound Sox4 and Cebpa
KO mice. Whereas Sox4 KO had no
significant hematopoietic phenotype, as
compared with wild-type (WT) control,
Cebpa-deficient mice had a larger LSK
population with superior proliferation,
which could be partially reversed by
Sox4 suppression. Again, in contrastCancer Cell 24, Nto Cebpa-deficient mice where myelo-
maturation was completely blocked,
Sox4 inactivation alone had no effect on
myeloid differentiation, but could partially
rescue the differentiation block in Cebpa
KO mice (Figure 1A).
To gain further insight into the roles of
SOX4 in C/EBPa leukemia, the authors
compared the pathological and molecular
features of murine AML models express-
ing bi-allelic Cebpa mutations (K/L mice)
versus SOX4-induced AML. Both AML
models shared the phenotypically
identical myeloid progenitor fraction II
(Mac-1lo/+c-Kit+) subpopulation as the
leukemic initiating cells (LICs), in which
elevated Sox4 expression was also
detected compared to WT counterpart.
Consistently, specific knockdown of
SOX4 suppressed replating activity of
LICs derived from K/L mice, suggesting
that the leukemogenic property of Cebpa
mutations is crucially mediated by SOX4.
At the molecular level, LICs from SOX4
AML and K/L AML shared common
gene expression signatures, which were
distinct from the LIC-enriched leukemic
GMP (L-GMP) from MLL-AF9- and
MOZ-TIF2-induced AML. Supervised
clustering analysis identified 80 genes
that were commonly upregulated in
normal HSC, and the fraction II in SOX4
and K/L AMLs as compared with normal
myeloid progenitors. Although some key
genes, previously shown to be critical
for MLL-AF9 L-GMP such as Mef2c and
prostaglandinendoperoxide synthase 1
(Ptgs1; also known as cyclooxygenase
1, Cox1) were also upregulated in LICs,
the rather limited overlapping between
the C/EBPa-SOX4 LICs and L-GMP
signatures (24 out of 420) suggests
distinct sets of transformation programsovember 11, 2013 ª2013 Elsevier Inc. 557
Figure 1. The Regulatory Interaction of SOX4 and C/EBPa in Normal and Malignant
Hematopoiesis
(A) In normal hematopoiesis, C/EBPa expression increases over the course of lineage commitment
and suppresses SOX4 expression through binding to the SOX4 promotor. Conversely, while SOX4 is
expressed at high levels in HSCs, it is downregulated during myeloid differentiation.
(B) C/EBPamutants (asterisk) fail to bind to theSOX4 promotor to repress its expression. Elevated expres-
sion of SOX4 confers superior self-renewal and proliferation activity in HSCs and myeloid progenitors.
Leukemic transformation by CEBPA mutation can be partially reversed by Sox4 knockdown.
C/EBPa-SOX4 leukemia also activates several pathways that are potentially critical for LIC activity (boxed
insets) including (1) activation of the WNT/b-catenin pathway by upregulation of PTGS1 expression and
direct binding of SOX4 to b-catenin for enhanced stabilization; (2) activation of TGF-b receptor type 2
(TGFBR2) expression resulting in enhanced FOXO3A mediated transcription; and (3) activation of EZH2
expression, resulting in alteration of the epigenetic landscape for oncogenic transformation. Because
no SOX4 inhibitor has been developed so far, targeting key molecules upregulated in C/EBPa-SOX4
LIC (indicated by triangles) may also be an alternative therapeutic avenue for this leukemia.
Cancer Cell
Previews
558 Cancer Cell 24, November 11, 2013 ª2013 Elsevier Inc.mediated by different initiating events.
Conversely, a high similarity in gene
expression profile was observed between
the mouse C/EBPa-SOX4 LIC and the
human AML with either bi-allelic CEBPA
mutations or silencing. Consistent with
the mouse data, shRNA-mediated sup-
pression of SOX4 expression in primary
human CEBPA mutated AML cells
partially restored granulocytic differen-
tiation in vivo upon transplantation
into immunocompromised NSG mice.
Together, these data reveal that SOX4 is
a crucial downstream effector to confer
enhanced self-renewal and differentia-
tion block in C/EBPa-deficient/mutated
cells (Figure 1B).
Although bi-allelic CEBPA mutations
associate with a relatively good prog-
nosis, a significant number of patients still
respond poorly to the current chemo-
therapy regimen, and, therefore, better
therapeutic strategies are needed (Zeisig
et al., 2012). Because Sox4 is largely
dispensable for normal hematopoiesis,
the identification of its critical functions
in C/EBPa leukemia reveals a potentially
attractive therapeutic avenue. To take
this interesting finding forward, future
efforts are needed to address some key
outstanding issues. Most of the work
presented in the current study is limited
to normal hematopoiesis and in vitro
transformation assays; therefore, it will
be essential to confirm the in vivo efficacy
of targeting SOX4 to suppress C/EBPa
leukemia. Will SOX4 suppression also be
effective in targeting CEBPA mutations
(e.g., H84L mutant) that do not affect the
p42/p30 ratio and are still able to repress
SOX4 expression? Also, the lack of a
relevant small molecule inhibitor against
SOX4 and the potential difficulty in target-
ing transcription factors may damper
its direct therapeutic translation. On the
other hand, recent studies have shown
that SOX4 directly activates the polycomb
group protein enhancer of zeste homolog
2 (EZH2) in breast cancer and is indis-
pensable for primary tumor growth and
metastasis (Tiwari et al., 2013). Small
molecule inhibitors and synthetic pep-
tides targeting EZH2 have already shown
promise in suppressing large diffuse
B cell lymphoma with EZH2 mutation
and MLL-AF9 transformed cells (Kim
et al., 2013; McCabe et al., 2012). It will
be of interest to determine if the action
of SOX4 in C/EBPa AML may also be
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Previewspartly mediated by EZH2 (Figure 1B). In
addition, other more tractable targets,
such as TGF-b-FOXO signaling and
PTGS1 (a key enzyme activating the Wnt/
b-catenin pathway), were also identified
in the LIC signature shared by both SOX4
and C/EBPa leukemias (Figure 1B). TGF-
b-FOXO signaling is required for the
maintenance of LICs in chronic myeloid
leukemia (Naka et al., 2010), whereas
inhibition of b-catenin suppresses AML
stem cells induced by MLL fusions
(Wang et al., 2010; Yeung et al., 2010)
(Figure 1B). Thus, future studies in delin-
eating the molecular mechanisms and
downstream targets mediating SOX4
oncogenic function will be instrumental
for both understanding the biology of thedisease and designing better therapeutic
strategies for C/EBPa leukemia.REFERENCES
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Tumor-infiltrating macrophages typically promote angiogenesis while suppressing antitumoral T cell re-
sponses. In this issue of Cancer Cell, Klug and colleagues report that clinically-feasible, low-dose irradiation
redirects macrophage differentiation from a tumor-promoting/immunosuppressive state to one that enables
cytotoxic T cells to infiltrate tumors and kill cancer cells, rendering immunotherapy successful in mice.Macrophages are components of a
stromal-cell network that orchestrates
the angiogenic and immunosuppressive
programming of neoplastic tissues (Hana-
han and Coussens, 2012). In growing
tumors, macrophages suppress T cells
both by growth stimulation of aberrant
and dysfunctional blood vessels, which
can limit T cell extravasation, and via direct
inhibitory effects on extravasated T cells.
Macrophage depletion, or alternatively
‘‘reprogramming,’’ may present opportu-
nities to restore T cell-mediated antitumor
immunity and increase the efficacy of can-
cer immunotherapies (De Palma andLewis, 2013). In this issue of Cancer Cell,
Klug et al. (2013) show that low-dose irra-
diation (LDI) of tumors or of isolated perito-
neal macrophages followed by adoptive
transfer promotes, in both cases, a differ-
entiation switch that results in macro-
phages that attenuate angiogenesis-
driven vascular abnormalities, facilitate
T cell infiltration, and enhance the efficacy
of immunotherapy in a genetically engi-
neered mouse model (GEMM) of cancer
and xenotransplanted human melanomas
(Klug et al., 2013) (Figure 1).
In the RIP1-Tag5 GEMM of pancreatic
islet carcinogenesis, LDI (2 Gy) enhancedtumor infiltration by CD8+ T cells, the pri-
mary effectors of antitumor immune
responses. Importantly, prior LDI also
enhanced tumor infiltration and the effi-
cacy of adoptively transferred, tumor-
specific CD8+ T cells. The combination
of prior LDI with T cell transfer dramati-
cally extended the survival of tumor-
bearing mice, while either treatment alone
had equivocal effects. The extended sur-
vival is remarkable, because this GEMM
develops multiple pancreatic tumors and
dozens of angiogenic dysplasias. The
antitumor efficacy of the combined treat-
ment was associated with two importantovember 11, 2013 ª2013 Elsevier Inc. 559
